176 related articles for article (PubMed ID: 33627787)
1. Mass-spectrometry-based proteomic correlates of grade and stage reveal pathways and kinases associated with aggressive human cancers.
Monsivais D; Vasquez YM; Chen F; Zhang Y; Chandrashekar DS; Faver JC; Masand RP; Scheurer ME; Varambally S; Matzuk MM; Creighton CJ
Oncogene; 2021 Mar; 40(11):2081-2095. PubMed ID: 33627787
[TBL] [Abstract][Full Text] [Related]
2. Bioinformatics Analysis of Global Proteomic and Phosphoproteomic Data Sets Revealed Activation of NEK2 and AURKA in Cancers.
Deb B; Sengupta P; Sambath J; Kumar P
Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32033228
[TBL] [Abstract][Full Text] [Related]
3. TTK, CDC25A, and ESPL1 as Prognostic Biomarkers for Endometrial Cancer.
Yang Q; Yu B; Sun J
Biomed Res Int; 2020; 2020():4625123. PubMed ID: 33282948
[TBL] [Abstract][Full Text] [Related]
4. Silencing TTK expression inhibits the proliferation and progression of prostate cancer.
Chen S; Wang J; Wang L; Peng H; Xiao L; Li C; Lin D; Yang K
Exp Cell Res; 2019 Dec; 385(1):111669. PubMed ID: 31605696
[TBL] [Abstract][Full Text] [Related]
5. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors.
Carretero J; Shimamura T; Rikova K; Jackson AL; Wilkerson MD; Borgman CL; Buttarazzi MS; Sanofsky BA; McNamara KL; Brandstetter KA; Walton ZE; Gu TL; Silva JC; Crosby K; Shapiro GI; Maira SM; Ji H; Castrillon DH; Kim CF; García-Echeverría C; Bardeesy N; Sharpless NE; Hayes ND; Kim WY; Engelman JA; Wong KK
Cancer Cell; 2010 Jun; 17(6):547-59. PubMed ID: 20541700
[TBL] [Abstract][Full Text] [Related]
6. Identification of hub genes associated with prognosis, diagnosis, immune infiltration and therapeutic drug in liver cancer by integrated analysis.
Lei X; Zhang M; Guan B; Chen Q; Dong Z; Wang C
Hum Genomics; 2021 Jun; 15(1):39. PubMed ID: 34187556
[TBL] [Abstract][Full Text] [Related]
7. Using cancer proteomics data to identify gene candidates for therapeutic targeting.
Monsivais D; Parks SE; Chandrashekar DS; Varambally S; Creighton CJ
Oncotarget; 2023 May; 14():399-412. PubMed ID: 37141409
[TBL] [Abstract][Full Text] [Related]
8. Better Agreement of Human Transcriptomic and Proteomic Cancer Expression Data at the Molecular Pathway Activation Level.
Raevskiy M; Sorokin M; Zakharova G; Tkachev V; Borisov N; Kuzmin D; Kremenchutckaya K; Gudkov A; Kamashev D; Buzdin A
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269755
[TBL] [Abstract][Full Text] [Related]
9. [Spindle assembly checkpoint complex-related genes TTK and MAD2L1 are over-expressed in lung adenocarcinoma: a big data and bioinformatics analysis].
Liu Z; Guo Z; Long L; Zhang Y; Lu Y; Wu D; Dong Z
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Oct; 40(10):1422-1431. PubMed ID: 33118511
[TBL] [Abstract][Full Text] [Related]
10. Integration and Analysis of CPTAC Proteomics Data in the Context of Cancer Genomics in the cBioPortal.
Wu P; Heins ZJ; Muller JT; Katsnelson L; de Bruijn I; Abeshouse AA; Schultz N; Fenyö D; Gao J
Mol Cell Proteomics; 2019 Sep; 18(9):1893-1898. PubMed ID: 31308250
[TBL] [Abstract][Full Text] [Related]
11. Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers.
Chen F; Chandrashekar DS; Varambally S; Creighton CJ
Nat Commun; 2019 Dec; 10(1):5679. PubMed ID: 31831737
[TBL] [Abstract][Full Text] [Related]
12. MASTL induces Colon Cancer progression and Chemoresistance by promoting Wnt/β-catenin signaling.
Uppada SB; Gowrikumar S; Ahmad R; Kumar B; Szeglin B; Chen X; Smith JJ; Batra SK; Singh AB; Dhawan P
Mol Cancer; 2018 Aug; 17(1):111. PubMed ID: 30068336
[TBL] [Abstract][Full Text] [Related]
13. CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute.
Zoppoli G; Solier S; Reinhold WC; Liu H; Connelly JW; Monks A; Shoemaker RH; Abaan OD; Davis SR; Meltzer PS; Doroshow JH; Pommier Y
Oncogene; 2012 Jan; 31(4):403-18. PubMed ID: 21765476
[TBL] [Abstract][Full Text] [Related]
14. Proteogenomics connects somatic mutations to signalling in breast cancer.
Mertins P; Mani DR; Ruggles KV; Gillette MA; Clauser KR; Wang P; Wang X; Qiao JW; Cao S; Petralia F; Kawaler E; Mundt F; Krug K; Tu Z; Lei JT; Gatza ML; Wilkerson M; Perou CM; Yellapantula V; Huang KL; Lin C; McLellan MD; Yan P; Davies SR; Townsend RR; Skates SJ; Wang J; Zhang B; Kinsinger CR; Mesri M; Rodriguez H; Ding L; Paulovich AG; Fenyö D; Ellis MJ; Carr SA;
Nature; 2016 Jun; 534(7605):55-62. PubMed ID: 27251275
[TBL] [Abstract][Full Text] [Related]
15. Multi-layered proteomic analyses decode compositional and functional effects of cancer mutations on kinase complexes.
Mehnert M; Ciuffa R; Frommelt F; Uliana F; van Drogen A; Ruminski K; Gstaiger M; Aebersold R
Nat Commun; 2020 Jul; 11(1):3563. PubMed ID: 32678104
[TBL] [Abstract][Full Text] [Related]
16. In-Silico Evaluation of Genetic Alterations in Ovarian Carcinoma and Therapeutic Efficacy of NSC777201, as a Novel Multi-Target Agent for TTK, NEK2, and CDK1.
Khedkar HN; Wang YC; Yadav VK; Srivastava P; Lawal B; Mokgautsi N; Sumitra MR; Wu ATH; Huang HS
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072728
[TBL] [Abstract][Full Text] [Related]
17. Identification and selective degradation of neopeptide-containing truncated mutant proteins in the tumors with high microsatellite instability.
Kim WK; Park M; Park M; Kim YJ; Shin N; Kim HK; You KT; Kim H
Clin Cancer Res; 2013 Jul; 19(13):3369-82. PubMed ID: 23674496
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase-deficient EphB6 receptor-dependent alterations in proteomic profiles of invasive breast carcinoma cells as determined by difference gel electrophoresis.
Kandpal RP
Cancer Genomics Proteomics; 2010; 7(5):253-60. PubMed ID: 20952760
[TBL] [Abstract][Full Text] [Related]
19. The panoramic picture of pepsinogen gene family with pan-cancer.
Shen S; Li H; Liu J; Sun L; Yuan Y
Cancer Med; 2020 Dec; 9(23):9064-9080. PubMed ID: 33067881
[TBL] [Abstract][Full Text] [Related]
20. Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer.
Petralia F; Tignor N; Reva B; Koptyra M; Chowdhury S; Rykunov D; Krek A; Ma W; Zhu Y; Ji J; Calinawan A; Whiteaker JR; Colaprico A; Stathias V; Omelchenko T; Song X; Raman P; Guo Y; Brown MA; Ivey RG; Szpyt J; Guha Thakurta S; Gritsenko MA; Weitz KK; Lopez G; Kalayci S; Gümüş ZH; Yoo S; da Veiga Leprevost F; Chang HY; Krug K; Katsnelson L; Wang Y; Kennedy JJ; Voytovich UJ; Zhao L; Gaonkar KS; Ennis BM; Zhang B; Baubet V; Tauhid L; Lilly JV; Mason JL; Farrow B; Young N; Leary S; Moon J; Petyuk VA; Nazarian J; Adappa ND; Palmer JN; Lober RM; Rivero-Hinojosa S; Wang LB; Wang JM; Broberg M; Chu RK; Moore RJ; Monroe ME; Zhao R; Smith RD; Zhu J; Robles AI; Mesri M; Boja E; Hiltke T; Rodriguez H; Zhang B; Schadt EE; Mani DR; Ding L; Iavarone A; Wiznerowicz M; Schürer S; Chen XS; Heath AP; Rokita JL; Nesvizhskii AI; Fenyö D; Rodland KD; Liu T; Gygi SP; Paulovich AG; Resnick AC; Storm PB; Rood BR; Wang P; ;
Cell; 2020 Dec; 183(7):1962-1985.e31. PubMed ID: 33242424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
